← Leaderboards
Priscilla Kaliopi Brastianos
Massachusetts General Hospital
$4,062,816
Attributed
$9,178,991
Total exposure
5
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.4M · FY2016–25$2M$1.5M$1M$500K$0
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$9,178,991 · 5
By mechanism
R01$8,279,234 · 3
R21$899,757 · 2
Top collaborators
- Scott Carter11 shared
- Elizabeth Gerstner5 shared
- Daniel P. Cahill2 shared
- Toni Choueiri2 shared
- Leif W Ellisen2 shared
Most similar at Massachusetts General Hospital
Same institution · by research overlap
- Anand Viswanathan$12,542,460
- Scott Carter$2,798,679
- Tayyaba Hasan$21,611,486
- Elizabeth Gerstner$2,756,329
- Mikhail I Papisov$3,140,887
Others in their field
Top investigators on “Clinical Trials”
- Lawrence Corey · Fred Hutchinson Cancer Center$824,102,536
- Sonia M Thomas · Research Triangle Institute$700,865,642
- David Heimbrook · Leidos Biomedical Research, Inc.$622,583,125
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$542,008,718
- Bambra Strokes · Ppd Development Lp$526,656,217
- Judith S. Currier · University Of California Los Angeles$504,273,077
Research focus
Clinical TrialsMutationTargeted TreatmentMetastatic Malignant Neoplasm To BrainPathway InteractionsMalignant NeoplasmsHistologyGenesTumorNovel TherapeuticsMetastatic Neoplasm To The Central Nervous SystemImmunotherapyChemotherapyInsightClonal EvolutionData SetResponseSystemic TherapyCommon NeoplasmLesionPhenotypeMissionPublic HealthUnited States National Institutes Of Health
Grant awards (16)
Elucidating resistance mechanisms and enhancing response to immune checkpoint blockade in central nervous system metastases from breast cancer$701,661
R01 · FY2025 · CA · contact PI
Elucidating resistance mechanisms and enhancing response to immune checkpoint blockade in central nervous system metastases from breast cancer$701,408
R01 · FY2024 · CA · contact PI
Using MRI and circulating tumor DNA to improve the interpretation of response to immunotherapy and targeted therapy in CNS metastases$646,356
R01 · FY2024 · CA
Using MRI and circulating tumor DNA to improve the interpretation of response to immunotherapy and targeted therapy in CNS metastases$666,767
R01 · FY2023 · CA
Identification of genomic drivers of brain metastases in lung adenocarcinoma$695,450
R01 · FY2022 · CA · contact PI
Using MRI and circulating tumor DNA to improve the interpretation of response to immunotherapy and targeted therapy in CNS metastases$666,767
R01 · FY2022 · CA
Identification of genomic drivers of brain metastases in lung adenocarcinoma$695,450
R01 · FY2021 · CA · contact PI
Using MRI and circulating tumor DNA to improve the interpretation of response to immunotherapy and targeted therapy in CNS metastases$694,319
R01 · FY2021 · CA
Using MRI and circulating tumor DNA to improve the interpretation of response to immunotherapy and targeted therapy in CNS metastases$711,319
R01 · FY2020 · CA
Identification of genomic drivers of brain metastases in lung adenocarcinoma$695,450
R01 · FY2020 · CA · contact PI
Identification of genomic drivers of brain metastases in lung adenocarcinoma$674,587
R01 · FY2019 · CA · contact PI
Identification of genomic drivers of brain metastases in renal cell carcinoma$181,867
R21 · FY2019 · CA · contact PI
Identification of genomic drivers of brain metastases in lung adenocarcinoma$729,700
R01 · FY2018 · CA · contact PI
Identification of genomic drivers of brain metastases in renal cell carcinoma$239,041
R21 · FY2018 · CA · contact PI
Impact of genetic alterations in meningioma on natural history and therapeutic response$215,484
R21 · FY2017 · NS
Impact of genetic alterations in meningioma on natural history and therapeutic response$263,365
R21 · FY2016 · NS